

Konrad Talbot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9359393/publications.pdf>

Version: 2024-02-01

40
papers

6,158
citations

186265

28
h-index

289244

40
g-index

41
all docs

41
docs citations

41
times ranked

9563
citing authors

#	ARTICLE	IF	CITATIONS
1	Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists. <i>Alzheimer's and Dementia</i> , 2022, 18, 478-497.	0.8	13
2	Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. <i>Biochemical Pharmacology</i> , 2020, 180, 114187.	4.4	57
3	Effects of Lifestyle Factors on Cognitive Resilience: Commentary on "What This Sunny, Religious Town in California Teaches Us About Living Longer". <i>Translational Stroke Research</i> , 2020, 11, 161-164.	4.2	4
4	Insulin resistance and cognitive test performance in elderly adults: National health and nutrition examination survey (NHANES). <i>Journal of the Neurological Sciences</i> , 2018, 388, 97-102.	0.6	12
5	Landscape of Conditional eQTL in Dorsolateral Prefrontal Cortex and Co-localization with Schizophrenia GWAS. <i>American Journal of Human Genetics</i> , 2018, 102, 1169-1184.	6.2	128
6	Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice—Potential Link to Cognitive Impairment in Schizophrenia. <i>Molecular Neurobiology</i> , 2017, 54, 1699-1709.	4.0	17
7	Novel GLP-1R/GIPR co-agonist "wincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury. <i>Experimental Neurology</i> , 2017, 288, 176-186.	4.1	34
8	Dysregulation of Specialized Delay/Interference-Dependent Working Memory Following Loss of Dysbindin-1A in Schizophrenia-Related Phenotypes. <i>Neuropsychopharmacology</i> , 2017, 42, 1349-1360.	5.4	17
9	Gene expression elucidates functional impact of polygenic risk for schizophrenia. <i>Nature Neuroscience</i> , 2016, 19, 1442-1453.	14.8	952
10	Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia. <i>Molecular Psychiatry</i> , 2015, 20, 1091-1100.	7.9	56
11	Mutations in the BLOC-1 Subunits Dysbindin and Muted Generate Divergent and Dosage-dependent Phenotypes. <i>Journal of Biological Chemistry</i> , 2014, 289, 14291-14300.	3.4	33
12	Newly identified precipitating factors in mechanical ventilation-induced brain damage: implications for treating ICU delirium. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 583-588.	2.8	7
13	Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning. <i>Hippocampus</i> , 2014, 24, 204-213.	1.9	28
14	Oxidative stress reduces levels of dysbindin-1A via its PEST domain. <i>Neurochemistry International</i> , 2014, 79, 65-69.	3.8	4
15	Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. <i>Neurodegenerative Disease Management</i> , 2014, 4, 31-40.	2.2	90
16	The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S12-25.	0.8	106
17	Mechanical Ventilation Triggers Hippocampal Apoptosis by Vagal and Dopaminergic Pathways. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 693-702.	5.6	66
18	Measuring cell-type specific differential methylation in human brain tissue. <i>Genome Biology</i> , 2013, 14, R94.	9.6	92

#	ARTICLE	IF	CITATIONS
19	MeCP2 Regulates the Synaptic Expression of a Dysbindin-BLOC-1 Network Component in Mouse Brain and Human Induced Pluripotent Stem Cell-Derived Neurons. <i>PLoS ONE</i> , 2013, 8, e65069.	2.5	38
20	Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function. <i>Hippocampus</i> , 2012, 22, 230-240.	1.9	84
21	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A β oligomers. <i>Journal of Clinical Investigation</i> , 2012, 122, 1339-1353.	8.2	697
22	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. <i>Journal of Clinical Investigation</i> , 2012, 122, 1316-1338.	8.2	1,431
23	The schizophrenia susceptibility factor dysbindin and its associated complex sort cargoes from cell bodies to the synapse. <i>Molecular Biology of the Cell</i> , 2011, 22, 4854-4867.	2.1	74
24	Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E962-70.	7.1	98
25	Synaptic Dysbindin-1 Reductions in Schizophrenia Occur in an Isoform-Specific Manner Indicating Their Subsynaptic Location. <i>PLoS ONE</i> , 2011, 6, e16886.	2.5	71
26	EHD1 is a synaptic protein that modulates exocytosis through binding to snapin. <i>Molecular and Cellular Neurosciences</i> , 2010, 45, 418-429.	2.2	15
27	The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research. <i>Progress in Brain Research</i> , 2009, 179, 87-94.	1.4	65
28	Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. <i>Human Molecular Genetics</i> , 2009, 18, 3851-3863.	2.9	113
29	Low sociability is associated with reduced size of the corpus callosum in the BALB/c inbred mouse strain. <i>Brain Research</i> , 2008, 1230, 211-217.	2.2	67
30	Caspase-3 Is Enriched in Postsynaptic Densities and Increased in Alzheimer's Disease. <i>American Journal of Pathology</i> , 2008, 173, 1488-1495.	3.8	171
31	Altered neuregulin 1's erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. <i>Nature Medicine</i> , 2006, 12, 824-828.	30.7	528
32	Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. <i>Human Molecular Genetics</i> , 2006, 15, 3041-3054.	2.9	141
33	Neurodevelopment, neuroplasticity, and new genes for schizophrenia. <i>Progress in Brain Research</i> , 2005, 147, 319-345.	1.4	115
34	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. <i>Journal of Clinical Investigation</i> , 2004, 113, 1353-1363.	8.2	371
35	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. <i>Journal of Clinical Investigation</i> , 2004, 113, 1353-1363.	8.2	206
36	A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. <i>Neurochemistry International</i> , 2000, 37, 17-31.	3.8	62

#	ARTICLE	IF	CITATIONS
37	Phospholipase pathway in Alzheimer's disease brains: decrease in GÎ±i in dorsolateral prefrontal cortex. Molecular Brain Research, 1999, 66, 188-190.	2.3	8
38	Feline islands of calleja complex: I. Cytoarchitectural organization and comparative anatomy. Journal of Comparative Neurology, 1988, 275, 553-579.	1.6	21
39	Feline islands of calleja complex: II. Cholinergic and cholinesterasic features. Journal of Comparative Neurology, 1988, 275, 580-603.	1.6	34
40	Evidence that efferents from the basolateral amygdala innervate the dorsolateral neostriatum in rats. Neuroscience Letters, 1984, 44, 71-75.	2.1	23